- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04669600
A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
Primary Objective:
- To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP)
Secondary Objectives:
- To assess the safety and tolerability of BIVV020
- To assess the pharmacokinetics of BIVV020
- To assess the response rate of treatment with BIVV020
- To assess the time to response
- To assess the effect of treatment with BIVV020 on the requirement for rescue ITP therapy
- To assess the immunogenicity of BIVV020
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study duration:
- Screening period: up to 56 days
- Transition period between last sutimlimab dose and first dose of BIVV020 (for participants who were previously receiving sutimlimab): 14 days, included as part of the 56-day Screening period. Treatment duration: Minimum 52 weeks.
Visit frequency:
- Day 1
- Day 4
- Weeks 1 to 6: Weekly
- Weeks 7 to 12: Every other week
- Weeks 13 to 24: Every 4 weeks
- Weeks 25+: At least every 8 weeks
- End of Study visit: 22 weeks after the last dose of BIVV020
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ostrava - Poruba, Czechia, 70852
- Investigational Site Number :2030002
-
-
-
-
-
Essen, Germany, 45147
- Investigational Site Number :2760001
-
-
-
-
-
Leiden, Netherlands, 2333 ZA
- Investigational Site Number :5280001
-
-
-
-
-
Palma de Mallorca, Spain, 07120
- Investigational Site Number :7240001
-
Sevilla, Spain, 41013
- Investigational Site Number :7240003
-
-
A Coruña [La Coruña]
-
La Coruña, A Coruña [La Coruña], Spain, 15006
- Investigational Site Number :7240002
-
-
-
-
London, City Of
-
London, London, City Of, United Kingdom, W12 0HS
- Investigational Site Number :8260002
-
-
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Investigational Site Number :8400001
-
-
Florida
-
Tamarac, Florida, United States, 33321
- Investigational Site Number :8400002
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria :
- Male and female participants ≥18 years of age at the time of signing the informed consent
- Confirmed diagnosis of primary ITP; for participants who previously received sutimlimab in study TDR16218 (NCT03275454), a response to sutimlimab must have been obtained, as defined by platelet count ≥30 × 10^9/L on 2 visits at least 7 days apart
For participants who have not previously received sutimlimab: persistent/chronic ITP (ITP lasting for ≥6 months) and all the following conditions:
- Platelet count ≤30 × 10^9/L on 2 occasions at least 5 days apart during the Screening Period;
- Lack of an adequate platelet count response (as defined by maintenance of sustained platelet count ≥30 × 109/L in the absence of bleeding) to at least 2 ITP treatments, 1 of which was a thrombopoietin receptor agonist. Other ITP treatments include: IVIg, anti-D immunoglobulin, corticosteroids, splenectomy, rituximab, cyclophosphamide, azathioprine, danazol, cyclosporin A, mycophenolate mofetil, or fostamatinib.
- If receiving weekly thrombopoietin receptor agonist dosing, the last dose must have been administered ≥7 days before the first dose of BIVV020. If receiving daily thrombopoietin receptor agonist dosing, the last dose must have been administered ≥24 hours before the first dose of BIVV020
- If applicable, concurrent administration of ITP medications (eg. corticosteroids, IVIg, azathioprine, danazol, cyclosporin A, mycophenolate mofetil, or thrombopoietin receptor agonists) is acceptable provided the participant has been on a stable dose for at least 1 month.
- If previously dosed with rituximab, the last dose of rituximab must have been administered at least 12 weeks before the first dose of BIVV020
- Documented vaccinations against encapsulated bacterial pathogens (Neisseria meningitidis, including serogroup B where available, Haemophilus influenzae, and Streptococcus pneumoniae) within 5 years of enrollment
- Contraceptive use for women of childbearing potential and men who were sexually active with a female partner of childbearing potential
Exclusion criteria:
Participants were excluded from the study if any of the following criteria apply:
- Clinically significant medical history or ongoing chronic illness that would jeopardize the safety of the participant or compromise the quality of the data derived from his/her participation in the study
- Clinical diagnosis of SLE
- Clinically relevant infection within the month prior to enrollment
- History of venous or arterial thrombosis within the year prior to enrollment
- Secondary ITP from any cause including lymphoma, chronic lymphocytic leukemia, and drug-induced thrombocytopenia
- Positive hepatitis B surface antigen (HBsAg) or active HCV infection
- HIV infection
- Pregnant or lactating women
- Hemoglobin level <10 g/dL
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SAR445088
Participants received SAR445088 (BIVV020).
|
Pharmaceutical form:solution for injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a Durable Platelet Response
Time Frame: From Week 3 to Week 24
|
A naive participant was a participant who did not use sutimlimab prior to enrollment.
A switcher was a participant who used sutimlimab prior to enrollment.
A naive participant was a responder if the platelet count was >=50 × 10^9/liter (L) at >=50 percent (%) of scheduled visits, or for participants with baseline platelet count <15 × 10^9/L, a >=20 × 10^9/L increase in platelet count from baseline at >=50% of scheduled visits, without receiving rescue immune thrombocytopenia (ITP) therapy.
A switcher was a responder if the maintenance platelet count was >=30 × 10^9/L at >=50% of scheduled visits, without receiving rescue ITP therapy.
|
From Week 3 to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (SAE)
Time Frame: From first study treatment administration (Day 1) up to Week 103
|
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment.
SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
TEAEs were AEs that developed after the first study treatment administration in the safety analysis period which was defined as the period from the first study intervention administration to the end of study (EOS) visit (up to Week 103).
|
From first study treatment administration (Day 1) up to Week 103
|
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology
Time Frame: On Days 1, 15, 29, at Weeks 8, 12, 24, and then every 8 weeks until the end of study (EOS) (Week 103)
|
Criteria for potentially clinically significant laboratory abnormalities (PCSA): White blood cells: less than (<)3.0
Giga/L (Non-Black [NB]) or <2.0 Giga/L (Black [B]), greater than or equal to (>=)16.0
Giga/L; Lymphocytes: greater than (>)4.0
Giga/L; Neutrophils: <1.5 Giga/L (NB) or <1.0 Giga/L (B); Monocytes: >0.7 Giga/L; Basophils: >0.1 Giga/L; Eosinophils: >0.5 Giga/L or >upper limit of normal (ULN) (if ULN >=0.5 Giga/L); Hemoglobin: less than or equal to (<=) 115 grams per liter (g/L) (Male[M]) or <=95 g/L (Female[F]), >=185 g/L (M) or >=165 g/L (F), Decrease from baseline (DFB) >=20 g/L; Hematocrit: <=0.37 volume/volume (v/v) (M) or <=0.32 v/v (F); Red blood cells (RBC): >=6 Tera/L; Platelets:<100 Giga/L, >=700 Giga/L.
Only the worst case during the treatment-emergent (TE) period for each participant with worsening from baseline is presented.
|
On Days 1, 15, 29, at Weeks 8, 12, 24, and then every 8 weeks until the end of study (EOS) (Week 103)
|
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Clinical Chemistry
Time Frame: On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
|
Criteria for PCSA: Blood Urea Nitrogen: >=17 millimole (mmol)/L; Creatinine: >=150 micromole (mcmol)/L (Adults), >=30% and <100% change from baseline, >=100% change from baseline; Potassium: <3 mmol/L, >=5.5 mmol/L; Sodium: <=129 mmol/L, >=160 mmol/L; Aspartate Aminotransferase (AST): >3 ULN, >5 ULN, >10 ULN, >20 ULN; Alanine Aminotransferase (ALT): >3 ULN, >5 ULN, >10 ULN, >20 ULN; Alkaline Phosphatase (ALP): >1.5 ULN; Bilirubin: >1.5 ULN, >2 ULN; ALT and Total Bilirubin: ALT >3 ULN and TBILI >2 ULN.
Only the worst case during the TE period for each participant with worsening from baseline is presented.
|
On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
|
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Coagulation
Time Frame: On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
|
The number of participants with PCSA for coagulation parameters during the TE period without PCSA definition by biological function are presented.
The parameters evaluated were prothrombin time, prothrombin international normalized ratio and activated partial thromboplastin time (APTT).
|
On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
|
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis
Time Frame: On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
|
Criteria for PCSA: potential of Hydrogen (pH) <=4.6, >=8.
Only the worst case during the TE period for each participant with worsening from baseline is presented.
|
On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
|
Plasma Concentrations of SAR445088 (BIVV020)
Time Frame: 1-hour post-dose on Day 1, on Days 8, 15, 29, 43, at Weeks 12, 16, 24, 32, 40, 48, 56, 64, 72, 80 and EOS visit, up to 103 weeks
|
Plasma samples were collected at specified timepoints.
|
1-hour post-dose on Day 1, on Days 8, 15, 29, 43, at Weeks 12, 16, 24, 32, 40, 48, 56, 64, 72, 80 and EOS visit, up to 103 weeks
|
Number of Responders to SAR445088 (BIVV020)
Time Frame: At Weeks 24 and 56
|
A participant was a responder if the platelet count was >=50 × 10^9/L and there was a greater than 2-fold increase from baseline, measured on 2 occasions at least 7 days apart with the absence of bleeding [bleeding score >=2 on the World Health Organization (WHO) bleeding scale] while the platelet counts were maintained above the threshold and lack of combination ITP therapy during this period.
WHO bleeding scores: 1=Petechiae; 2=Mild blood loss; 3=Gross blood loss; and 4=Debilitating blood loss.
|
At Weeks 24 and 56
|
Time to First Platelet Response
Time Frame: From Baseline (Day 1) up to Week 56
|
Time to first platelet response was defined as greater than or equal to each of the following values: 50 × 10^9/L or 100 × 10^9/L (confirmed by 2 measurements at least 7 days apart).
It was calculated as date of first occurrence of confirmed platelet count response before rescue therapy.
|
From Baseline (Day 1) up to Week 56
|
Percentage of Participants Who Did Not Require Rescue Therapy for an Acute Episode of Thrombocytopenia After Week 3
Time Frame: Up to Week 84
|
Data was collected to assess the effect of treatment with SAR445088 (BIVV020) on the requirement for rescue ITP therapy.
|
Up to Week 84
|
Number of Participants With Anti-Drug Antibody (ADAs) Response to SAR445088 (BIVV020)
Time Frame: Up to Week 103
|
Plasma samples were analyzed for the presence of ADAs for SAR445088 (BIVV020) using validated assays.
Treatment-induced ADA was defined as ADAs that developed during the treatment-emergent period and without pre-existing ADA.
Pre-existing ADA was defined as ADAs present in samples drawn before first study treatment administration.
Treatment-boosted ADA positive was defined as pre-existing ADA (i.e., ADA positive at baseline) that was boosted at least a 9-fold increase of titer values during the treatment-emergent period than the baseline.
Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive during the treatment-emergent period.
Inconclusive ADA was defined as the one that could not irrefutably be classified as with or without treatment-emergent ADA.
|
Up to Week 103
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Sciences & Operations, Sanofi
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura, Thrombocytopenic
- Purpura
- Purpura, Thrombocytopenic, Idiopathic
- Thrombocytopenia
Other Study ID Numbers
- PDY16894
- 2020-004162-18 (EudraCT Number)
- U1111-1253-2343 (Other Identifier: UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Thrombocytopenia (ITP)
-
Gruppo Italiano Malattie EMatologiche dell'AdultoNot yet recruitingITP - Immune Thrombocytopenia | Chronic ITP | Refractory ITP
-
HutchmedActive, not recruitingImumune Thrombocytopenia(ITP) Human Mass BalanceChina
-
AmgenCompletedThrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic PurpuraUnited States, Canada, Australia
-
Peking University People's HospitalNot yet recruitingCorticosteroid-resistant or Relapsed ITP
-
Institute of Hematology & Blood Diseases Hospital...Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaboratorsRecruitingPrimary Immune Thrombocytopenia (ITP)China
-
argenxWithdrawnPrimary Immune Thrombocytopenia (ITP)
-
Novartis PharmaceuticalsRecruitingPrimary Immune Thrombocytopenia (ITP)China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
-
University Children's Hospital BaselNovartis Pharmaceuticals; Stiftung zur Förderung medizinischer und biologischer... and other collaboratorsActive, not recruiting
-
AmgenCompletedIdiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingChronic Primary Immune Thrombocytopenia (ITP)China
Clinical Trials on SAR445088 (BIVV020)
-
Bioverativ, a Sanofi companyActive, not recruitingChronic Inflammatory Demyelinating PolyradiculoneuropathyCanada, Spain, China, Italy, United States, France, Germany, Netherlands, Poland, Serbia
-
Bioverativ, a Sanofi companyCompletedAutoimmune Haemolytic AnaemiaUnited States, Germany, Italy, Netherlands, Norway, United Kingdom
-
Bioverativ, a Sanofi companyActive, not recruitingAutoimmune Haemolytic AnaemiaNetherlands, Germany, Italy, Norway, United Kingdom
-
SanofiRecruitingChronic Inflammatory Demyelinating Polyradiculoneuropathy | Polyneuropathy, Inflammatory Demyelinating, ChronicUnited States
-
SanofiRecruitingTransplant RejectionGermany, Italy, Spain, United States, Canada, France, Sweden
-
SanofiNot yet recruiting